286 related articles for article (PubMed ID: 17573894)
41. Locally recurrent prostate cancer after initial radiation therapy: a comparison of salvage radical prostatectomy versus cryotherapy.
Pisters LL; Leibovici D; Blute M; Zincke H; Sebo TJ; Slezak JM; Izawa J; Ward JF; Scott SM; Madsen L; Spiess PE; Leibovich BC
J Urol; 2009 Aug; 182(2):517-25; discussion 525-7. PubMed ID: 19524984
[TBL] [Abstract][Full Text] [Related]
42. Intensity-modulated radiotherapy of the prostate after cryotherapy: initial experience.
Hepel JT; MacAusland SG; Long JP; Wazer DE; DiPetrillo T
Urology; 2008 Dec; 72(6):1310-4; discussion 1314. PubMed ID: 18502482
[TBL] [Abstract][Full Text] [Related]
43. Sequential treatment for recurrent localized prostate cancer.
Van Der Poel HG; Moonen L; Horenblas S
J Surg Oncol; 2008 Apr; 97(5):377-82. PubMed ID: 18360820
[TBL] [Abstract][Full Text] [Related]
44. Hemoglobin levels do not predict biochemical outcome for localized prostate cancer treated with neoadjuvant androgen-suppression therapy and external-beam radiotherapy.
Pai HH; Ludgate C; Pickles T; Paltiel C; Agranovich A; Berthelet E; Duncan G; Kim-Sing C; Kwan W; Lim J; Liu M; Tyldesley S
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):990-8. PubMed ID: 16682135
[TBL] [Abstract][Full Text] [Related]
45. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
Demanes DJ; Brandt D; Schour L; Hill DR
Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
[TBL] [Abstract][Full Text] [Related]
46. Salvage prostate cryoablation: initial results from the cryo on-line data registry.
Pisters LL; Rewcastle JC; Donnelly BJ; Lugnani FM; Katz AE; Jones JS
J Urol; 2008 Aug; 180(2):559-63; discussion 563-4. PubMed ID: 18554664
[TBL] [Abstract][Full Text] [Related]
47. Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality.
Chung CS; Chen MH; Cullen J; McLeod D; Carroll P; D'Amico AV
Urology; 2008 Jan; 71(1):136-40. PubMed ID: 18242382
[TBL] [Abstract][Full Text] [Related]
48. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy.
Ho AY; Burri RJ; Cesaretti JA; Stone NN; Stock RG
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):16-22. PubMed ID: 19289266
[TBL] [Abstract][Full Text] [Related]
49. Salvage radical prostatectomy for radiorecurrent prostate cancer: indications and results.
Darras J; Joniau S; Van Poppel H
Eur J Surg Oncol; 2006 Nov; 32(9):964-9. PubMed ID: 16815663
[TBL] [Abstract][Full Text] [Related]
50. Recognizing false biochemical failure calls after radiation with or without neo-adjuvant androgen deprivation for prostate cancer.
Denham JW; Kumar M; Gleeson PS; Lamb DS; Joseph D; Atkinson C; Matthews J; Tai KH; Spry NA; Christie D; Turner S; Greer PB; D'Este C; Steigler A
Int J Radiat Oncol Biol Phys; 2009 Jun; 74(2):404-11. PubMed ID: 19176272
[TBL] [Abstract][Full Text] [Related]
51. Prostate-specific antigen level at initiation of hormonal therapy after prostate-specific antigen failure following prostatectomy or radiotherapy and therapeutic response.
Alexander BM; Chen MH; Carroll P; D'Amico AV
Urology; 2007 Aug; 70(2):320-3. PubMed ID: 17826497
[TBL] [Abstract][Full Text] [Related]
52. PSA nadir is a significant predictor of treatment failure after high-intensity focussed ultrasound (HIFU) treatment of localised prostate cancer.
Ganzer R; Rogenhofer S; Walter B; Lunz JC; Schostak M; Wieland WF; Blana A
Eur Urol; 2008 Mar; 53(3):547-53. PubMed ID: 17662520
[TBL] [Abstract][Full Text] [Related]
53. Decision analyses in consideration of treatment strategies for patients with biochemical failure after curative therapy on clinically localized prostate cancer in the prostate-specific antigen era.
Shimizu F; Igarashi A; Fukuda T; Kawachi Y; Minowada S; Ohashi Y; Fujime M
Jpn J Clin Oncol; 2007 Oct; 37(10):763-74. PubMed ID: 17956899
[TBL] [Abstract][Full Text] [Related]
54. Validation of a nomogram to predict disease progression following salvage radiotherapy after radical prostatectomy: results from the SEARCH database.
Moreira DM; Jayachandran J; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Stephenson AJ; Freedland SJ
BJU Int; 2009 Nov; 104(10):1452-6. PubMed ID: 19466946
[TBL] [Abstract][Full Text] [Related]
55. Focal salvage guided by T2-weighted and dynamic contrast-enhanced magnetic resonance imaging for prostate cancer recurrences.
Moman MR; van den Berg CA; Boeken Kruger AE; Battermann JJ; Moerland MA; van der Heide UA; van Vulpen M
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):741-6. PubMed ID: 19804948
[TBL] [Abstract][Full Text] [Related]
56. Third-generation salvage cryotherapy for radiorecurrent prostate cancer: a centre's experience.
Philippou P; Yap T; Chinegwundoh F
Urol Int; 2012; 88(2):137-44. PubMed ID: 22285952
[TBL] [Abstract][Full Text] [Related]
57. Efficacy of salvage radiotherapy plus 2-year androgen suppression for postradical prostatectomy patients with PSA relapse.
Choo R; Danjoux C; Gardner S; Morton G; Szumacher E; Loblaw DA; Cheung P; Pearse M
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):983-9. PubMed ID: 19409726
[TBL] [Abstract][Full Text] [Related]
58. A model that predicts the probability of positive imaging in prostate cancer cases with biochemical failure after initial definitive local therapy.
Choueiri TK; Dreicer R; Paciorek A; Carroll PR; Konety B
J Urol; 2008 Mar; 179(3):906-10; discussion 910. PubMed ID: 18207194
[TBL] [Abstract][Full Text] [Related]
59. Use of different definitions of biochemical failure after external beam radiotherapy changes conclusions about relative treatment efficacy for localized prostate cancer.
Kupelian PA; Mahadevan A; Reddy CA; Reuther AM; Klein EA
Urology; 2006 Sep; 68(3):593-8. PubMed ID: 16979731
[TBL] [Abstract][Full Text] [Related]
60. High-intensity focused ultrasound for localized prostate cancer: initial experience with a 2-year follow-up.
Challacombe BJ; Murphy DG; Zakri R; Cahill DJ
BJU Int; 2009 Jul; 104(2):200-4. PubMed ID: 19220245
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
